If you administer subcutaneous injections regularly, such as once or multiple times daily, you will need to rotate the injection sites. This means that you shouldn’t inject medication into the same ...

PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...

The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option for patients. The subcutaneous form of Keytruda showed to deliver the same ...

Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...

Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors. In an interview with CURE®, Dr. Eric K.

Some experts believe offering a subcutaneous version of nivolumab could make PD-1 inhibitors available to new groups of patients who currently lack access, such as those in rural areas. This article ...

A subcutaneous injection that can administer an immunotherapy in 1–2 minutes using domestic technology has been developed and approved in the United States. Immunotherapies are usually given ...

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio One subcutaneous injection of REGEN-COV — ...

SQ Innovation, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its drug-device combination ...

At the time of analysis, no cases of post injection delirium syndrome were reported. A once-monthly subcutaneous formulation of olanzapine (TEV-’749) was found to improve symptoms in patients with ...